Advertisement

Melanoma pp 485-500 | Cite as

Melanoma Clinical Staging (Historical and Current)

  • Michael E. Egger
  • Jeffrey E. GershenwaldEmail author
Reference work entry

Abstract

Melanoma staging has evolved as our understanding of clinical and pathological risk factors have improved and surgical staging strategies have matured. The current American Joint Committee on Cancer (AJCC) melanoma staging system is based on the tumor (T), node (N), metastasis (M) system, similar to most other solid tumors; criteria that define TNM have changed over time. The T category is determined by primary tumor thickness and presence or absence of ulceration; the N category takes into account both the number of clinically occult and clinically detected lymph node metastases, as well as the presence or absence of non-nodal regional metastases. The M category is defined by anatomic site of disease and lactate dehydrogenase levels. Sentinel lymph node biopsy has become a standard assessment technique by which T2-T4 melanomas, and some T1 melanomas, are staged. Taken together, the melanoma staging system allows for accurate risk stratification of large subsets of melanoma patients that can help guide clinicians and patients regarding prognosis. In the future, melanoma staging may be complemented by validated clinical tools based on multiple clinical, pathological, and molecular risk factors, and may provide a more precise individualized risk assessment for melanoma patients.

Keywords

Melanoma Staging Sentinel lymph node biopsy Prognosis Metastasis Lymphadenectomy Lymph node dissection Risk assessment 

References

  1. Abusaif S, Jradi Z, Held L et al (2013) S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Res 23(5):396–401PubMedCrossRefPubMedCentralGoogle Scholar
  2. Azzola MF, Shaw HM, Thompson JF et al (2003) Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 97(6):1488–1498PubMedCrossRefPubMedCentralGoogle Scholar
  3. Balch CM, Murad TM, Soong SJ et al (1978) A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark’s and Breslow’s staging methods. Ann Surg 188(6):732–742PubMedPubMedCentralCrossRefGoogle Scholar
  4. Balch CM, Murad TM, Soong SJ et al (1979) Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 43(3):883–888PubMedCrossRefPubMedCentralGoogle Scholar
  5. Balch CM, Wilkerson JA, Murad TM et al (1980) The prognostic significance of ulceration of cutaneous melanoma. Cancer 45(12):3012–3017PubMedCrossRefPubMedCentralGoogle Scholar
  6. Balch CM, Soong SJ, Murad TM et al (1983) A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1(2):126–134PubMedCrossRefPubMedCentralGoogle Scholar
  7. Balch CM, Buzaid AC, Soong SJ et al (2001a) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635–3648PubMedCrossRefPubMedCentralGoogle Scholar
  8. Balch CM, Soong SJ, Gershenwald JE et al (2001b) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16): 3622–3634PubMedCrossRefPubMedCentralGoogle Scholar
  9. Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206PubMedPubMedCentralCrossRefGoogle Scholar
  10. Balch CM, Gershenwald JE, Soong SJ et al (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28(14):2452–2459PubMedPubMedCentralCrossRefGoogle Scholar
  11. Barnhill RL, Katzen J, Spatz A et al (2005) The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 32(4):268–273PubMedCrossRefPubMedCentralGoogle Scholar
  12. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181(3):193–201PubMedPubMedCentralGoogle Scholar
  13. Bartlett EK, Gupta M, Datta J et al (2014) Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol 21(3):1016–1023PubMedCrossRefPubMedCentralGoogle Scholar
  14. Beahrs OH, American Joint Committee on Cancer, American Cancer Society (1992) Manual for staging of cancer, 4th edn. Lippincott, PhiladelphiaGoogle Scholar
  15. Bittner M, Meltzer P, Chen Y et al (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795):536–540PubMedCrossRefPubMedCentralGoogle Scholar
  16. Blaheta HJ, Ellwanger U, Schittek B et al (2000) Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 114(4):637–642PubMedCrossRefPubMedCentralGoogle Scholar
  17. Bostick PJ, Morton DL, Turner RR et al (1999) Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17(10):3238–3244PubMedCrossRefPubMedCentralGoogle Scholar
  18. Bowen GM, Chang AE, Lowe L et al (2000) Solitary melanoma confined to the dermal and/or subcutaneous tissue: evidence for revisiting the staging classification. Arch Dermatol 136(11):1397–1399PubMedCrossRefPubMedCentralGoogle Scholar
  19. Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172(5):902–908PubMedPubMedCentralCrossRefGoogle Scholar
  20. Breslow A (1975) Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 182(5):572–575PubMedPubMedCentralCrossRefGoogle Scholar
  21. Callender GG, Gershenwald JE, Egger ME et al (2012) A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg 214(4):608–617; discussion 617–9PubMedCrossRefPubMedCentralGoogle Scholar
  22. Carlson GW, Murray DR, Lyles RH et al (2003) The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 10(5):575–581PubMedCrossRefPubMedCentralGoogle Scholar
  23. Castiglione R, Ihle MA, Heydt C et al (2016) The impact of sequencing on diagnosis and treatment of malignant melanoma. Expert Rev Mol Diagn 16(4):423–433PubMedCrossRefPubMedCentralGoogle Scholar
  24. Clark WH Jr, From L, Bernardino EA et al (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29(3): 705–727PubMedPubMedCentralGoogle Scholar
  25. Clark WH Jr, Elder DE, Guerry D et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24): 1893–1904PubMedCrossRefPubMedCentralGoogle Scholar
  26. Cochran AJ, Huang RR, Lee J et al (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6(9):659–670PubMedCrossRefPubMedCentralGoogle Scholar
  27. Collins GS, Reitsma JB, Altman DG et al (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg 102(3):148–158PubMedCrossRefPubMedCentralGoogle Scholar
  28. Debarbieux S, Duru G, Dalle S et al (2007) Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol 157(1):58–67PubMedCrossRefPubMedCentralGoogle Scholar
  29. Deichmann M, Benner A, Bock M et al (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891–1896PubMedCrossRefPubMedCentralGoogle Scholar
  30. Dewar DJ, Newell B, Green MA et al (2004) The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 22(16):3345–3349PubMedCrossRefPubMedCentralGoogle Scholar
  31. Dick J, Lang N, Slynko A et al (2016) Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 8(9): 1033–1044PubMedCrossRefPubMedCentralGoogle Scholar
  32. Diem S, Kasenda B, Spain L et al (2016) Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 114(3):256–261PubMedPubMedCentralCrossRefGoogle Scholar
  33. Edge SB, American Joint Committee on Cancer (2010) AJCC Cancer Staging Manual, 7th edn. Springer, New YorkGoogle Scholar
  34. Egberts F, Kotthoff EM, Gerdes S et al (2012) Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer 48(5): 695–702PubMedCrossRefPubMedCentralGoogle Scholar
  35. Egger ME, Bhutiani N, Farmer RW et al (2016) Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes. Surgery 159(5):1412–1421PubMedCrossRefPubMedCentralGoogle Scholar
  36. Eton O, Legha SS, Moon TE et al (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16(3):1103–1111PubMedCrossRefPubMedCentralGoogle Scholar
  37. Fleming ID, American Joint Committee on Cancer, American Cancer Society et al (1997) AJCC Cancer Staging Manual, 5th edn. Lippincott-Raven, PhiladelphiaGoogle Scholar
  38. Gandini S, Ferrucci PF, Botteri E et al (2016) Prognostic significance of hematological profiles in melanoma patients. Int J Cancer 139:1618–1625PubMedCrossRefPubMedCentralGoogle Scholar
  39. Gaudy-Marqueste C, Archier E, Grob A et al (2014) Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. Eur J Cancer 50(6): 1120–1124PubMedCrossRefPubMedCentralGoogle Scholar
  40. Ge L, Vilain RE, Lo S et al (2016) Breslow thickness measurements of melanomas around American Joint Committee on Cancer staging cut-off points: imprecision and terminal digit bias have important implications for staging and patient management. Ann Surg Oncol 23:2658–2663PubMedCrossRefPubMedCentralGoogle Scholar
  41. Gerami P, Cook RW, Russell MC et al (2015) Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72(5):780–5e3PubMedCrossRefPubMedCentralGoogle Scholar
  42. Gershenwald JE, Thompson W, Mansfield PF et al (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17(3):976–983PubMedCrossRefPubMedCentralGoogle Scholar
  43. Gershenwald JE, Scolyer RA, Hess KR, et al (2017a) Melanoma of the skin. In: Amin MB, Edge SB, Greene FL, et al eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; pp. 563–585Google Scholar
  44. Gershenwald JE, Scolyer RA, Hess KR et al (2017b) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin.  https://doi.org/10.3322/caac.21409. [Epub ahead of print]Google Scholar
  45. Gimotty PA, Elder DE, Fraker DL et al (2007) Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 25(9): 1129–1134PubMedCrossRefPubMedCentralGoogle Scholar
  46. Goydos JS, Ravikumar TS, Germino FJ et al (1998) Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transcriptase polymerase chain reaction. J Am Coll Surg 187(2):182–188; discussion 188–90PubMedCrossRefPubMedCentralGoogle Scholar
  47. Hilari JM, Mangas C, Xi L et al (2009) Molecular staging of pathologically negative sentinel lymph nodes from melanoma patients using multimarker, quantitative real-time rt-PCR. Ann Surg Oncol 16(1):177–185PubMedCrossRefPubMedCentralGoogle Scholar
  48. Hochberg M, Lotem M, Gimon Z et al (2002) Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 146(2):244–249PubMedCrossRefPubMedCentralGoogle Scholar
  49. Huang SK, Hoon DS (2016) Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol 10(3):450–463PubMedCrossRefPubMedCentralGoogle Scholar
  50. Jacquelot N, Enot DP, Flament C et al (2016) Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest 126(3):921–937PubMedPubMedCentralCrossRefGoogle Scholar
  51. Jaeger J, Koczan D, Thiesen HJ et al (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13(3):806–815PubMedCrossRefPubMedCentralGoogle Scholar
  52. Kammula US, Ghossein R, Bhattacharya S et al (2004) Serial follow-up and the prognostic significance of reverse transcriptase-polymerase chain reaction – staged sentinel lymph nodes from melanoma patients. J Clin Oncol 22(19):3989–3996PubMedCrossRefPubMedCentralGoogle Scholar
  53. Kattan MW, Hess KR, Amin MB et al (2016) American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin 66:370PubMedPubMedCentralCrossRefGoogle Scholar
  54. Kelderman S, Heemskerk B, van Tinteren H et al (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63(5):449–458PubMedPubMedCentralGoogle Scholar
  55. Kesmodel SB, Karakousis GC, Botbyl JD et al (2005) Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12(6):449–458PubMedCrossRefPubMedCentralGoogle Scholar
  56. Kimsey TF, Cohen T, Patel A et al (2009) Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol 16(5):1176–1183PubMedCrossRefPubMedCentralGoogle Scholar
  57. Koh SS, Wei JP, Li X et al (2012) Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol 25(6): 828–837PubMedCrossRefPubMedCentralGoogle Scholar
  58. Kuo CT, Hoon DS, Takeuchi H et al (2003) Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 21(19):3566–3572PubMedCrossRefPubMedCentralGoogle Scholar
  59. Long GV, Weber JS, Infante JR et al (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8):871–878PubMedCrossRefPubMedCentralGoogle Scholar
  60. Ma MW, Medicherla RC, Qian M et al (2012) Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol 25(7):1000–1010PubMedCrossRefPubMedCentralGoogle Scholar
  61. Mahar AL, Compton C, Halabi S et al (2016) Critical assessment of clinical prognostic tools in melanoma. Ann Surg Oncol 23:2753PubMedCrossRefPubMedCentralGoogle Scholar
  62. Mangas C, Hilari JM, Paradelo C et al (2006) Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol 13(7):910–918PubMedCrossRefPubMedCentralGoogle Scholar
  63. McMasters KM, Wong SL, Edwards MJ et al (2001) Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 130(2):151–156PubMedCrossRefPubMedCentralGoogle Scholar
  64. McMasters KM, Egger ME, Edwards MJ et al (2016) Final results of the sunbelt melanoma trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol 34(10):1079–1086PubMedPubMedCentralCrossRefGoogle Scholar
  65. Morton DL, Wen DR, Wong JH et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127(4):392–399PubMedCrossRefPubMedCentralGoogle Scholar
  66. Morton DL, Thompson JF, Essner R et al (1999) Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230(4): 453–463; discussion 463–5PubMedPubMedCentralCrossRefGoogle Scholar
  67. Panasiti V, Curzio M, Roberti V et al (2013) Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients. Dermatology 227(1):55–61PubMedCrossRefPubMedCentralGoogle Scholar
  68. Rajkumar S, Watson IR (2016) Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer 115(2): 145–155PubMedPubMedCentralCrossRefGoogle Scholar
  69. Ranieri JM, Wagner JD, Azuaje R et al (2002) Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 9(10):975–981PubMedCrossRefPubMedCentralGoogle Scholar
  70. Read RL, Haydu L, Saw RP et al (2015) In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol 22(2):475–481PubMedCrossRefPubMedCentralGoogle Scholar
  71. Reintgen D, Cruse CW, Wells K et al (1994) The orderly progression of melanoma nodal metastases. Ann Surg 220(6):759–767PubMedPubMedCentralCrossRefGoogle Scholar
  72. Ribuffo D, Gradilone A, Vonella M et al (2003) Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol 10(4):396–402PubMedCrossRefPubMedCentralGoogle Scholar
  73. Romanini A, Manca G, Pellegrino D et al (2005) Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol 16(11):1832–1840PubMedCrossRefPubMedCentralGoogle Scholar
  74. Ross MI, Reintgen D, Balch CM (1993) Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9(3): 219–223PubMedPubMedCentralGoogle Scholar
  75. Rousseau DL Jr, Ross MI, Johnson MM et al (2003) Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10(5):569–574PubMedCrossRefPubMedCentralGoogle Scholar
  76. Scoggins CR, Ross MI, Reintgen DS et al (2006) Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24(18):2849–2857PubMedCrossRefPubMedCentralGoogle Scholar
  77. Shaikh L, Sagebiel RW, Ferreira CM et al (2005) The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol 141(6):739–742PubMedCrossRefPubMedCentralGoogle Scholar
  78. Shivers SC, Wang X, Li W et al (1998) Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 280(16):1410–1415PubMedCrossRefPubMedCentralGoogle Scholar
  79. Simeone E, Gentilcore G, Giannarelli D et al (2014) Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 63(7):675–683PubMedCrossRefPubMedCentralGoogle Scholar
  80. Sirott MN, Bajorin DF, Wong GY et al (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10): 3091–3098PubMedCrossRefPubMedCentralGoogle Scholar
  81. Smoller BR, Balch CB, Balzer BL et al (2016) Protocol for the examination of specimens from patients with melanoma of the skin January 2016. Available at: http://www.cap.org/web/home/resources/cancer-reporting-tools/cancer-protocol-templates. Accessed 12 Apr 2016
  82. Sondak VK, Taylor JM, Sabel MS et al (2004) Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11(3):247–258PubMedCrossRefPubMedCentralGoogle Scholar
  83. Soong SJ, Ding S, Coit D et al (2010) Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 17(8):2006–2014PubMedCrossRefPubMedCentralGoogle Scholar
  84. Starz H, Siedlecki K, Balda BR (2004) Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 11(Suppl 3): 162S–168SPubMedCrossRefPubMedCentralGoogle Scholar
  85. Thompson JF, McCarthy WH, Bosch CM et al (1995) Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5(4):255–260PubMedCrossRefPubMedCentralGoogle Scholar
  86. Thompson JF, Soong SJ, Balch CM et al (2011) Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 29(16): 2199–2205PubMedPubMedCentralCrossRefGoogle Scholar
  87. Ulrich J, Bonnekoh B, Bockelmann R et al (2004) Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer 40(18):2812–2819PubMedCrossRefPubMedCentralGoogle Scholar
  88. Vallacchi V, Vergani E, Camisaschi C et al (2014) Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res 74(1):130–140PubMedCrossRefPubMedCentralGoogle Scholar
  89. van Akkooi AC, Nowecki ZI, Voit C et al (2008) Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248(6):949–955PubMedCrossRefPubMedCentralGoogle Scholar
  90. van der Leest RJ, van Steenbergen LN, Hollestein LM et al (2014) Conditional survival of malignant melanoma in The Netherlands: 1994–2008. Eur J Cancer 50(3): 602–610PubMedCrossRefPubMedCentralGoogle Scholar
  91. Van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A et al (1996) Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 149(3):759–764PubMedPubMedCentralGoogle Scholar
  92. Wanebo HJ, Fortner JG, Woodruff J et al (1975) Selection of the optimum surgical treatment of stage I melanoma by depth of microinvasion: use of the combined microstage technique (Clark-Breslow). Ann Surg 182(3): 302–315PubMedPubMedCentralCrossRefGoogle Scholar
  93. Wang X, Heller R, VanVoorhis N et al (1994) Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 220(6):768–774PubMedPubMedCentralCrossRefGoogle Scholar
  94. White RL Jr, Ayers GD, Stell VH et al (2011) Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol 18(13):3593–3600PubMedPubMedCentralCrossRefGoogle Scholar
  95. Xing Y, Chang GJ, Hu CY et al (2010) Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 116(9):2234–2241PubMedPubMedCentralGoogle Scholar
  96. Yee VS, Thompson JF, McKinnon JG et al (2005) Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 12(6):429–439PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Surgical Oncology, Unit 1484The University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Melanoma and Skin CenterThe University of Texas MD Anderson Cancer CenterHoustonUSA

Section editors and affiliations

  • Keith T. Flaherty
    • 1
  • Boris C. Bastian
    • 2
  • Hensin Tsao
    • 3
    • 4
  • F. Stephen Hodi
    • 5
    • 6
  1. 1.Henri and Belinda Termeer Center for Targeted TherapiesMGH Cancer CenterBostonUSA
  2. 2.UCSF Helen Diller Family Comprehensive Cancer CenterSan FranciscoUSA
  3. 3.AuburndaleUSA
  4. 4.Harvard-MIT Health Sciences and TechnologyCambridgeUSA
  5. 5.FraminghamUSA
  6. 6.Department of Medicine, Brigham and Women's HospitalDana-Farber Cancer InstituteBostonUSA

Personalised recommendations